Sign in
Not yet taking people in United StatesPhase 2

Tests OT-101 with pembrolizumab in pleural mesothelioma that stopped responding to immunotherapy

Tests OT-101 plus pembrolizumab in adults with pleural mesothelioma not responding to checkpoint inhibition.

Key facts

Who runs it
Oncotelic Inc.
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Status
Not yet recruiting
Phase
Phase 2
People taking part
63 people, planned
Started
Jun 2025
Expected to end
Dec 2029
Type of study
Interventional
Treatments tested
  • OT-101
Record updated
15 March 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with malignant pleural mesothelioma whose disease got worse after treatment with a checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA-4).

Age
At least 18 years
Sex
Men and women
Disease stage
Malignant pleural mesothelioma confirmed by tissue test, with measurable disease (mRECIST), which progressed after anti-PD-1, anti-PD-L1 or anti-CTLA-4 treatment. ECOG performance status 0 to 1.
Earlier treatment
Must have progressed on an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody, alone or with other therapies including platinum chemotherapy. No other cancer treatment in the 28 days before the trial.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Active brain metastases or carcinomatous meningitis
  • Active autoimmune disease treated in the past 2 years, or immunodeficiency
  • Pneumonitis or interstitial lung disease that needed steroids, or current one
  • Past solid organ transplant, active infection needing treatment, or known hepatitis B or active hepatitis C

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Participants must have progressed on treatment with an anti-PD-1 or anti-PD-L1 mAb or anti-CTLA-4 mAb administered either as monotherapy or in combination with other therapies including platinum-based chemotherapy. PD-1 treatment progression is defined by meeting all of the following criteria:; Has demonstrated disease progression after anti-PD-1 or anti-PD-L1 or anti-CTLA-4 mAb as defined by the investigator
  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Malignant Pleural Mesothelioma will be enrolled in this study
  • Male participants: A male participant must agree to use contraception as detailed in Appendix 4 of this protocol during the treatment period and for at least 90 days, corresponding to time needed to eliminate any study treatment(s) (e.g. 5 terminal half-lives for pembrolizumab) plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period
  • Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:; Not a woman of childbearing potential (WOCBP) OR; A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days/weeks corresponding to time needed to eliminate any study treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment
  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
  • Have measurable disease by Revised mRECIST
  • Provide a baseline biopsy prior to the start of therapy. Archival biopsy is acceptable
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Have adequate organ function. Specimens must be collected within 10 days prior to the start of study intervention

Who cannot take part

  • Has received prior systemic anti-cancer therapy including investigational agents within 28 days prior to study therapy
  • Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
  • Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The following are exceptions to this criterion:; Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 10 days prior to first dose of study intervention
  • Has had an allogenic tissue/solid organ transplant
  • Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • A WOCBP who has a positive urine pregnancy test within 72 hours prior to agent administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment

Where in United States

  • University of PennsylvaniaPhiladelphia, United StatesContact: Melina Marmarelis, MDNot yet recruiting

About the trial

What the trial wants to find out

This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.

The group in the trial

  • Drug OT-101 plus pembrolizumabTreatment being tested

    OT-101 will be administered at a RP2D dose/m2/day for 4 days continuously and 10 days off every two weeks via a portable infusion pump. Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks.

    Treatment: OT-101

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Trial of TGF-β Inhibition (OT-101) With Anti-PD-1 (Pembrolizumab) in Patients With Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition
Plain-language title
Tests OT-101 with pembrolizumab in pleural mesothelioma that stopped responding to immunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 March 2024